Cervical Cancer

According to the AACR, “Cervical cancer usually develops slowly over time. Before cancer appears in the cervix, the cells of the cervix go through changes known as dysplasia, in which abnormal cells begin to appear in the cervical tissue. Those abnormal cells may become cancer cells and start to grow and spread more deeply into the cervix and to surrounding areas.

Infection of the cervix with human papillomavirus (HPV) is almost always the cause of cervical cancer. Not all women with HPV infection, however, will develop cervical cancer. Women who do not regularly have tests to detect HPV or abnormal cells in the cervix are at increased risk of cervical cancer.

The vast majority of cervical cancers could be prevented with Pap tests and HPV vaccination.

Cervical cancer, an often preventable cancer, will be diagnosed in an estimated 13,960 women living in the United States in 2023, and some 4,310 women are expected to die of the disease, according to the National Cancer Institute.”

https://www.aacr.org/patients-caregivers/cancer/cervical-cancer/

FDG PET CT study showing uterine and cervical masses with abnormal FDG activities, highly suspicious for uterine cervical cancer. In the upper abdomen, there are two foci of abnormal FDG activity corresponding to adrenal glands, R > L, suspicious for bilateral adrenal metastases.

National Comprehensive Cancer Network® (NCCN®) Comments on PET/CT application to Cervical Cancer

For patients with stage II disease or greater, PET/CT (preferred) or CT should be performed within 3 to 6 months of completing therapy; pelvic MRI is optional. Additional imaging should be guided by symptomatology and clinical concern for recurrent/metastatic disease (page MS 13-14)

Radiologic imaging studies (including PET/CT) are recommended for stage IB2 or greater disease, especially for evaluation of nodal or extrapelvic tumor (see Principles of Imaging in the NCCN Guidelines for Cervical Cancer). (page MS-11)”

Source: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf

Permission Pending from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer Version 1.2023 — April 28, 2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed August 28, 2023 To view the most recent and complete version of the guideline, go online to NCCN.org.